OppenheimerFunds Inc. purchased a new position in Orthofix International N.V. (NASDAQ:OFIX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,990 shares of the medical device company’s stock, valued at approximately $305,000.
Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Orthofix International N.V. by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 759,298 shares of the medical device company’s stock worth $27,471,000 after buying an additional 26,114 shares during the period. Ameriprise Financial Inc. increased its position in Orthofix International N.V. by 23.5% in the first quarter. Ameriprise Financial Inc. now owns 423,655 shares of the medical device company’s stock worth $16,162,000 after buying an additional 80,710 shares during the period. State Street Corp increased its position in Orthofix International N.V. by 5.6% in the fourth quarter. State Street Corp now owns 364,267 shares of the medical device company’s stock worth $13,179,000 after buying an additional 19,395 shares during the period. Gabelli Funds LLC increased its position in Orthofix International N.V. by 0.3% in the first quarter. Gabelli Funds LLC now owns 291,450 shares of the medical device company’s stock worth $11,119,000 after buying an additional 1,000 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Orthofix International N.V. by 122.5% in the first quarter. Bank of New York Mellon Corp now owns 242,068 shares of the medical device company’s stock worth $9,236,000 after buying an additional 133,281 shares during the period. Institutional investors and hedge funds own 99.68% of the company’s stock.
Orthofix International N.V. (NASDAQ:OFIX) opened at 47.35 on Thursday. The firm has a 50-day moving average of $45.44 and a 200-day moving average of $40.49. The company’s market cap is $854.38 million. Orthofix International N.V. has a one year low of $32.51 and a one year high of $48.55.
Orthofix International N.V. (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.01. The firm had revenue of $108.90 million for the quarter, compared to analysts’ expectations of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 10.04%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.41 earnings per share. On average, analysts predict that Orthofix International N.V. will post $1.55 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/10/oppenheimerfunds-inc-purchases-new-position-in-orthofix-international-n-v-nasdaqofix-updated-updated.html.
A number of equities analysts recently commented on OFIX shares. BidaskClub downgraded Orthofix International N.V. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised shares of Orthofix International N.V. from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. Ladenburg Thalmann Financial Services initiated coverage on shares of Orthofix International N.V. in a report on Wednesday, June 14th. They issued a “buy” rating and a $53.25 target price on the stock. SunTrust Banks, Inc. initiated coverage on shares of Orthofix International N.V. in a report on Tuesday, May 23rd. They issued a “buy” rating and a $49.00 target price on the stock. Finally, BTIG Research initiated coverage on shares of Orthofix International N.V. in a report on Wednesday, June 21st. They issued a “buy” rating and a $52.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $51.88.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
